Navigation Links
OVA1 Improves Ovarian Cancer Detection Over CA 125 Blood Test and Clinical Assessment
Date:5/24/2011

o an adequate job of identifying early stage ovarian cancer," states Dr. Frederick Ueland, author of the paper and principal investigator of the OVA1 clinical trial. "In this study, OVA1 identified 98% of early stage epithelial ovarian cancers compared to 68% identified by CA 125. Furthermore, OVA1 identified 93% of premenopausal early stage cancers compared to only 36% identified by CA 125."

The OVA1 test incorrectly identified non-cancerous masses about twice as often as CA 125 or clinical assessment. A higher false positive rate may increase patient distress and the number of surgeries that specialists unnecessarily perform. Dr. Ueland noted in the study that in current clinical practice only 12% to 40% of patients referred to gynecologic oncologists have malignant disease, and therefore the OVA1 false positive rate is in line with real-world referral patterns.

Of more importance is the decreased number of false negatives or undetected cancers when OVA1 is added to a physician's assessment, which is reduced from 28% to 8% in non-gynecologic oncologist assessment and from 21% to 1% in gynecologic oncologist assessment. This translates into potentially more cancers being referred to a gynecologic oncologist for initial surgery. The investigators go on to say, "hopefully, earlier referral of patients with ovarian cancer will improve survival and reduce the number of required re-operation."

The study manuscript follows online publication on May 9, 2011 in Obstetrics & Gynecology that suggested OVA1 may be appropriate in place of CA 125 in ACOG referral guidelines for women under evaluation for an ovarian mass ("Performance of the American College of Obstetricians and Gynecologists' Ovarian Tumor Referral Guidelines With a Multivariate Index Assay," by Dr. Rachel Miller.) The two articles are based on data from the same study and both are published in the June 2011 print edition.

About OVA1

OVA1 is the first test cleared b
'/>"/>

SOURCE Quest Diagnostics
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study
2. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
3. New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
4. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
5. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
6. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
7. Tailored Clopidogrel Dosing Improves PCI Outcomes
8. Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder
9. SuperGens DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine
10. Gene Therapy Improves Vision in Patients with Congenital Retinal Disease
11. Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... N.C. , May 24, 2013  Regulatory ... the forefront of many organizations, priority list. ... medical device sectors understand a strong Medical ... challenges in clinical development, market education , ... to create a vital bridge between an organization ...
(Date:5/24/2013)... N.J. , May 24, 2013  BD (Becton, Dickinson ... medical technology company, announced today that it will present at ... on Thursday, May 30, 2013, at 10:40 a.m. (ET). ... accessed from the BD corporate website at www.bd.com/investors ... 2013.    About BD BD is ...
(Date:5/24/2013)... Calif. , May 24, 2013 /PRNewswire-iReach/ -- Phoenix ... leading non-profit substance abuse services organization, is hosting its ... Beverly Hills Hotel on June 6, 2013.  More than ... raise funds for the adolescent residential treatment centers, family ... as honor individuals whose accomplishments have positive influences on ...
Breaking Medicine Technology:Building Medical Affairs Capabilities to Ensure Organizational Success across Key Operational Areas 2Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg 2Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg 3
... Meets Primary Endpoint in,Rheumatoid Arthritis Patients Who ... -, NUTLEY, N.J., July 10, 2007 /PRNewswire/ ... Actemra Radiate (RheumAtoiD,ArthritIs Study in Anti-TNF FailurEs) ... with moderate to severe rheumatoid,arthritis (RA) who ...
... Humira Estimated to Increase the,Maximal Steady ... 100%,-, SAN DIEGO, July 09, 2007 ... biopharmaceutical company developing and,commercializing recombinant human ... the Enhanze(TM) Technology clinical trial,demonstrating improved ...
Cached Medicine Technology:Actemra (tocilizumab) Third Phase III Study Results Show,Significant Improvement in Symptoms of Patients with Rheumatoid,Arthritis 2Actemra (tocilizumab) Third Phase III Study Results Show,Significant Improvement in Symptoms of Patients with Rheumatoid,Arthritis 3Actemra (tocilizumab) Third Phase III Study Results Show,Significant Improvement in Symptoms of Patients with Rheumatoid,Arthritis 4Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 2Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 3Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 4Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 5
(Date:5/24/2013)... May 24, 2013 ShopPharmacyCounter.com PhenObestin 37.5 ... ShopPharmacyCounter.com have announced price reductions on their popular PhenObestin ... which helps clients to lose weight as effortlessly as ... 37.5 by more than 50%. , Bottles have been ... time and all orders will receive free shipping. ...
(Date:5/24/2013)... Range Kleen Mfg. strives to “TCOTC.” Our ... from the President's desk to the Shipping Dock.” We hold ... and having passion while creating excellence and quality being results ... to do the right thing and what better way to ... by devastation. , Throughout the year Range Kleen donates to ...
(Date:5/24/2013)... Before you start the grill, before you watch ... Lee Gifford and Hoda Kotb on the Today Show on Memorial ... ideas to Kathie Lee and Hoda, including the new LawnBott® LB75 ... and women in the military who made the ultimate sacrifice for ... time with friends and family and enjoy the day. With ...
(Date:5/24/2013)... York (PRWEB) May 24, 2013 ... DePuy hip recall continue to move forward in courts ... to documents filed in California’s San Francisco Superior Court ... an expedited trial of her DePuy hip lawsuit is ... DePuy Orthopaedics, Inc., et al., No. CGC11508806; Calif. Super. ...
(Date:5/24/2013)... for heart failure appear to have better odds of ... morning, a new study finds. Death rates and ... admitted in January, on Fridays and overnight, according to ... Saturday in Portugal at the annual meeting of the ... "The fact that patients admitted right before ...
Breaking Medicine News(10 mins):Health News:ShopPharmacyCounter.com PhenObestin 37.5 Summer Sale Now On 2Health News:Range Kleen Partners with Berndes in Red Cross Promotion: Taking Care of Oklahoma 2Health News:LawnBott® Visits the Today Show with Kathie Lee and Hoda 2Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 2Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 3Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 4Health News:Monday Best Time for Hospitalization With Heart Failure, Study Says 2
... of SEIU UHW will hold a news conference at 3 p.m. ... to release newly obtained information showing that ousted union President Sal ... attorney that some of the actions may be illegal but took ... to cover them up. , , The documents detailing ...
... WAYNE, N.J., July 9 Today, Bayer HealthCare Pharmaceuticals ... designed to make infusion of recombinant factor VIII easier ... caregivers. The centerpiece of the program is an ... allows patients to practice the technique of self-injection without ...
... who had first period before age 12 are at increased risk ... Among women with ovarian cancer, those who had their first menstrual ... menstrual cycles over a lifetime are more likely to die of ... study shows. , U.S. researchers analyzed data on 410 women, aged ...
... cardiac CT for low-risk chest pain patients in the emergency ... may reduce a patients length of stay and hospital charges, ... School of Medicine, Seattle, WA. The SOC workup, which is ... tests, ECGs and nuclear stress testing. , , Fifty ...
... ... ... Drug Information Association (DIA), in collaboration with the Generic Pharmaceutical Association (GPhA), PhRMA, ... Registration--FDA and Industry: Overview and Lessons Learned on SPL (August 11-12; Philadelphia, PA) ...
... ... ... The American Academy of Orthopaedic Surgeons (AAOS) has opened the call for submissions to its ... musculoskeletal health issues and healthy behaviors in the care of bones, joints and muscles. ...
Cached Medicine News:Health News:Newly Obtained Information Shows That Ousted Union Leaders Plotted and Covered Up Wrongdoing 2Health News:Bayer HealthCare Launches Hemophilia Self-Infusion Training Program 2Health News:Bayer HealthCare Launches Hemophilia Self-Infusion Training Program 3Health News:Bayer HealthCare Launches Hemophilia Self-Infusion Training Program 4Health News:Bayer HealthCare Launches Hemophilia Self-Infusion Training Program 5Health News:Early Menstruation Lowers Odds of Surviving Ovarian Cancer 2Health News:Early Menstruation Lowers Odds of Surviving Ovarian Cancer 3Health News:DIA Workshop Features Industry and FDA for Discussion of Best Practices for Electronic Establishment Registration and Product Listing 2Health News:Got Moving Stories? Calling All Reporters, Writers, Producers and Editors 2Health News:Got Moving Stories? Calling All Reporters, Writers, Producers and Editors 3
Phaco chopper, a combination of a modified microfinger and a pointed "quick chop" tip. For use in the left hand....
The titanium sleeve is coated with hydroxyapatite (HA) which allows vascular ingrowth, firmly secures the peg in the sphere, and enhances biocompatibility. To hold prosthetic eye. For improved occula...
... Brown nucleus cracker with straight shaft ... viscoelastic, thereby, maintains anterior chamber depth ... Accomplished with a design that keeps ... blocking outflow of viscoelastic. Available with ...
Epilation forceps straight ends size 3.5"....
Medicine Products: